Presage Biosciences (anti-cancer drug candidate voruciclib) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Presage Biosciences (anti-cancer drug candidate voruciclib) General Information
Description
A clinical-stage, oral and selective cyclin-dependent kinase (CDK) inhibitor for oncology treatment. The drug has the potential to overcome mechanisms of drug resistance and significantly improve patient outcomes.
Contact Information
Corporate Office
- 530 Fairview Avenue North
- Suite 1000
- Seattle, WA 98109
- United States
Corporate Office
- 530 Fairview Avenue North
- Suite 1000
- Seattle, WA 98109
- United States
Presage Biosciences (anti-cancer drug candidate voruciclib) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Presage Biosciences (anti-cancer drug candidate voruciclib) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Presage Biosciences (anti-cancer drug candidate voruciclib) FAQs
-
Where is Presage Biosciences (anti-cancer drug candidate voruciclib) headquartered?
Presage Biosciences (anti-cancer drug candidate voruciclib) is headquartered in Seattle, WA.
-
What industry is Presage Biosciences (anti-cancer drug candidate voruciclib) in?
Presage Biosciences (anti-cancer drug candidate voruciclib)’s primary industry is Buildings and Property.
-
Is Presage Biosciences (anti-cancer drug candidate voruciclib) a private or public company?
Presage Biosciences (anti-cancer drug candidate voruciclib) is a Private company.
-
What is the current valuation of Presage Biosciences (anti-cancer drug candidate voruciclib)?
The current valuation of Presage Biosciences (anti-cancer drug candidate voruciclib) is .
-
What is Presage Biosciences (anti-cancer drug candidate voruciclib)’s current revenue?
The current revenue for Presage Biosciences (anti-cancer drug candidate voruciclib) is .
-
Who are Presage Biosciences (anti-cancer drug candidate voruciclib)’s investors?
Presage ( Discovery Tools) has invested in Presage Biosciences (anti-cancer drug candidate voruciclib).
-
When was Presage Biosciences (anti-cancer drug candidate voruciclib) acquired?
Presage Biosciences (anti-cancer drug candidate voruciclib) was acquired on 05-Sep-2017.
-
Who acquired Presage Biosciences (anti-cancer drug candidate voruciclib)?
Presage Biosciences (anti-cancer drug candidate voruciclib) was acquired by Lite Strategy.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process